Client Result
Orrick Advises Ipsen on Acquisition of Liver Disease Treatment Innovator Albireo
1 minute read | January.09.2023

1 minute read | January.09.2023
June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
December.20.2021
November.19.2021
Orrick is advising Workday on its definitive agreement to acquire VNDLY for approximately $510 million.
June.25.2021